Jubilant Pharmova Ltd.

Financial

	Jubilant Pharmova	Pfizer	Strides Pharma Scien
Operational Metrics
API Sector
Japan DMF Filings	15.0 .	n/a	n/a
US DMF Filings	98.0 .	n/a	n/a
Australia DMF fillings	14.0 .	n/a	n/a
Canada DMF fillings	40.0 .	n/a	n/a
Pharmaceutical Sector
Number of ANDA's Filed in USA	100.0 .	n/a	260.0 .
Number of ANDA's Approved By USFDA	62.0 .	n/a	235.0 .
Number of ANDA's Filed in Europe	38.0	n/a	n/a
Number of ANDA's Approved in Europe	37.0	n/a	n/a
Number of ANDA's Filed in Canada	24.0	n/a	n/a
Number of ANDA's Approved by Canada	24.0	n/a	n/a
R&D as a % of Total Sales	0.61 %	n/a	2.24 %
Financials
5 yr Average ROE	10.45 %	18.17 %	-1.06 %
5yr average Equity Multiplier	2.05	1.31	2.7
5yr Average Asset Turnover Ratio	0.64	0.6	0.45
5yr Avg Net Profit Margin	8.17 %	23.14 %	0.77 %
Price to Book	2.17	5.76	4.1
P/E	152.67	37.58	0.0
5yr Avg Cash Conversion Cycle	-3.54 Days	-26.61 Days	-89.35 Days
Inventory Days	78.49 Days	48.38 Days	71.49 Days
Days Receivable	54.89 Days	20.98 Days	73.25 Days
Days Payable	167.25 Days	83.8 Days	261.28 Days
5yr Average Interest Coverage Ratio	4.68	173.5	0.64
5yr Avg ROCE	10.85 %	23.74 %	6.23 %
5yr Avg Operating Profit Margin	20.24 %	35.56 %	14.43 %
5 yr average Debt to Equity	0.71	0.0	1.04
5yr CAGR Net Profit	n/a	69.5 %	n/a
5yr Average Return on Assets	5.11 %	13.93 %	-0.26 %
Shareholdings
Promoter Holding	50.68 %	63.92 %	25.88 %
Share Pledged by Promoters	0.0	0.0	72.7 %
Change in Promoter Holding (3 Yrs)	0.0	0.0	-3.79 %
Change in Mutual Fund Holding (3 Yrs)	1.49 %	-0.7 %	-4.24 %

Business

	Jubilant Pharmova	Pfizer	Strides Pharma Scien
Product Wise Break-Up	Product Wise Break-Up Radiopharmaceuticals 40.74 Contract Manufacturing 18.57 Solid dosage formulations 11.58 Active Pharmaceutical Ingredient (API) 10.08 Anti-allergic 9.69 Contract Research and Development Services 8.37 India branded pharmaceuticals 0.57 Nutritional products 0 Specialty intermediates 0 Life science chemicals 0 Pharmaceutical 0 Others 0.4	Product Wise Break-Up Active Pharmaceutical Ingredient (API) 0 Specialty intermediates 0 0 Anti-allergic 0 Solid dosage formulations 0 Contract Manufacturing 0 Radiopharmaceuticals 0 Life science chemicals 0 Pharmaceutical 100.0 Nutritional products 0 India branded pharmaceuticals 0	Product Wise Break-Up Active Pharmaceutical Ingredient (API) 0 Specialty intermediates 0 0 Anti-allergic 0 Solid dosage formulations 0 Contract Manufacturing 0 Radiopharmaceuticals 0 Life science chemicals 0 Pharmaceutical 100.0 Nutritional products 0 India branded pharmaceuticals 0
Segment Break-Up	Segment Break-Up Radiopharma 45.86 Drug discovery and development solutions 16.31 CDMO Sterile Injectables 15.69 Generics 11.29 Allergy Immunotherapy 10.86 Proprietary Novel Drugs 0 Life Science Ingredients 0 Pharmaceuticals 0	-	-
Location Wise Break-Up	Location Wise Break-Up Americas and Europe 89.61 Rest of the World 8.0 India 2.39 China 0 Asia (excluding India) 0 Australia 0 Africa 0 Europe 0 North America 0	Location Wise Break-Up Asia (excluding India) 0 India 97.16 Africa 0 North America 0 Europe 0 China 0 Australia 0 Rest of the World 2.84 Americas and Europe 0	Location Wise Break-Up Asia Pacific 1.25 India 0.59 Africa 12.22 North America 52.22 Europe 22.69 China 0 Australia 8.45 Rest of the World 0 Americas and Europe 0 Others 2.58
Operating Profit Break-Up	Operating Profit Break-Up Radiopharma 48.64 Allergy Immunotherapy 26.62 CDMO Sterile Injectables 14.56 Contract Research and Development 10.18 Generics 0 Proprietary Novel Drugs 0 Life Science Ingredients 0 Pharmaceuticals 0 Pharmaceutical 0	-	Operating Profit Break-Up CDMO Sterile Injectables 0 Pharmaceuticals 0 Generics 0 Allergy Immunotherapy 0 Contract Research and Development 0 Life Science Ingredients 0 Pharmaceutical 100.0 Radiopharma 0 Proprietary Novel Drugs 0
Capex	Capex Contract Research and Development 24.13 Pharmaceuticals 20.33 Proprietary Novel Drugs 3.39 Life Science Ingredients 0 Others 52.15	-	-
Asset Break-Up	Asset Break-Up Contract Research and Development 13.83 Proprietary Novel Drugs 2.04 Life Science Ingredients 0 Pharmaceuticals 0 Bio-Pharmaceutical 0 Pharmaceutical 0 Others 84.13	-	Asset Break-Up Pharmaceuticals 0 Contract Research and Development 0 Bio-Pharmaceutical 3.1 Life Science Ingredients 0 Pharmaceutical 96.9 Proprietary Novel Drugs 0

Jubilant Pharmova Ltd.

SIGN UP FOR FREE